Fortress Biotech(NASDAQ) FBIOP

Current Price$18.70

Market CapN/A

Since IPO (2017)+72%

5 Year+7%

1 Year+165%

1 Month-6%

Fortress Biotech last closing stock price
Metric	Price	Date
Last close	USD 18.89	2026-07-24

Fortress Biotech stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+0.96%	USD 18.71	2026-07-17
1 month	-6.16%	USD 20.13	2026-06-24
3 month	+32.56%	USD 14.25	2026-04-24
Year to date	+99.05%	USD 9.49	2025-12-31
1 year	+165.31%	USD 7.12	2025-07-24
3 year	+28.47%	USD 14.70	2023-07-25
5 year	+6.55%	USD 17.73	2021-07-23
Since inception	+71.99%	USD 10.98	2017-11-14

Fortress Biotech Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$66.16M

Net Income (TTM)

$127.77M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.30 (Low)

Dividend

$0.00

Beta (Volatility)

0.30 (Low)

Price

$18.70

Volume

11,490.961

Open

$18.71

Price

$18.70

Volume

11,490.961

Open

$18.71

Previous Close

$18.89

Daily Range

$18.55 - $18.90

52-Week Range

$6.27 - $21.43

Estimated Earnings Date

Aug 17, 2026

Dividend

$0.00

Beta (Volatility)

0.30 (Low)

Price

$18.70

Volume

11,490.961

Open

$18.71

Previous Close

$18.89

Daily Range

$18.55 - $18.90

52-Week Range

$6.27 - $21.43

Estimated Earnings Date

Aug 17, 2026

FBIOP News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Fortress Biotech

Fortress Biotech, Inc. is a biopharmaceutical company focused on developing and commercializing innovative biopharmaceutical products. The company specializes in dermatology and other therapeutic areas, offering a diverse portfolio of products aimed at addressing unmet medical needs.

Products and Services

Dermatology products including Emrosi and Qbrexza
Intravenous Tramadol for post-operative pain management
Early-stage candidates targeting various diseases, including cancer and genetic disorders

Growth Outlook

Recent quarterly revenue reached $16.04 million, indicating strong market demand
Significant cash reserves of $255.84 million support ongoing research and development
Expansion into new therapeutic areas enhances potential for future revenue growth

Financial Highlights

Net income for Q1 2026 was $110.37 million, showcasing profitability
Gross profit margin improved to 54.2% in the latest quarter
Current ratio of 2.86 indicates strong liquidity position

Fortress Biotech, Inc. has established itself as a key player in the biopharmaceutical industry, with a focus on innovative solutions for various medical conditions. The company's diverse product offerings, including established dermatology treatments and promising early-stage candidates, position it well for future growth. Recent financial performance highlights, including a substantial net income and strong liquidity, reflect the company's operational efficiency and market potential. With a solid cash position, Fortress Biotech is well-equipped to continue its research and development efforts, potentially leading to new product launches and increased market share.

AI Generated • Jul 2, 2026

Industry

Biotechnology

Sector

Health Care

Headquarters

Bay Harbor Islands, FL 33154, US

FBIOP Financials

Key Financial Metrics (TTM)

Gross Margin

64.51%

Operating Margin

-84.36%

Net Income Margin

193.12%

Return on Equity

163.88%

Return on Capital

-56.55%

Return on Assets

35.80%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.39%

Stock Overview

Market Cap

N/A

Shares Outstanding

Volume

11.49K

Avg. Volume

23.67K

Financials (TTM)

Gross Profit

$42.68M

Operating Income

-$55.81M

EBITDA

$148.02M

Operating Cash Flow

$157.64M

Capital Expenditure

$0.00

Free Cash Flow

$157.64M

Cash & ST Invst.

$255.84M

Total Debt

$53.63M

Fortress Biotech Performance Analysis

Fortress Biotech sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	24.9%
Q3	2025-09-30	7.4%
Q4	2025-12-31	-8.8%
Q1	2026-03-31	-0.3%

Fortress Biotech sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	193.8%
Q3	2025-09-30	-75.6%
Q4	2025-12-31	-281.8%
Q1	2026-03-31	1510.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$16.04M

+22.1%

Gross Profit

$8.69M

+4.1%

Gross Margin

54.21%

N/A

Market Cap

N/A

Market Cap/Employee

N/A

Employees

N/A

Net Income

$110.37M

+1142.8%

EBITDA

$147.36M

+802.1%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$255.84M

+180.1%

Total Debt

$53.63M

-27.8%

Accounts Receivable

$25.51M

+39.1%

Inventory

$9.29M

-25.6%

Long Term Debt

$48.91M

-30.3%

Short Term Debt

$4.72M

+17.0%

Return on Assets

35.80%

N/A

Return on Invested Capital

-22.02%

N/A

Free Cash Flow

$203.85M

+1142.0%

Operating Cash Flow

$203.85M

+1142.0%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

EQEquillium, Inc.

EQEquillium, Inc.$2.49-7.43%

COEPCoeptis Therapeutics Holdings, Inc.

COEPCoeptis Therapeutics Holdings, Inc.$10.99-8.57%

IPSCCentury Therapeutics, Inc.

IPSCCentury Therapeutics, Inc.$2.11-2.76%

CUECue Biopharma, Inc.

CUECue Biopharma, Inc.$32.12-2.93%

VTVTvTv Therapeutics Inc.

VTVTvTv Therapeutics Inc.$30.73-2.94%

SNTISenti Biosciences, Inc.

SNTISenti Biosciences, Inc.$0.40-5.34%

GNTAGenenta Science S.p.A.

GNTAGenenta Science S.p.A.$1.59-3.64%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

INTCIntel

INTCIntel$92.32-0.08%

NOKNokia

NOKNokia$9.10-0.06%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$7.42-0.04%

ONDSOndas

ONDSOndas$7.80-0.02%

TAT&T

TAT&T$24.13+0.05%

FFord Motor Company

FFord Motor Company$14.37+0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$14.48+0.07%

Questions About FBIOP

What is the current price of Fortress Biotech?

Fortress Biotech is trading at $18.89 per share.

What is the 52-week range for Fortress Biotech?

Over the past 52 weeks, Fortress Biotech has traded between $6.27 and $21.43.

How much debt does Fortress Biotech have?

Fortress Biotech total debt is unavailable.

How much cash does Fortress Biotech have on hand?

Fortress Biotech does not have cash on hand data available.

What is Fortress Biotech’s dividend yield?

Fortress Biotech does not currently have a dividend yield.

Fortress Biotech(NASDAQ) FBIOP

Fortress Biotech Financials at a Glance

FBIOP News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Fortress Biotech

FBIOP Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Fortress Biotech Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About FBIOP

What is the current price of Fortress Biotech?

What is the 52-week range for Fortress Biotech?

How much debt does Fortress Biotech have?

How much cash does Fortress Biotech have on hand?

What is Fortress Biotech’s dividend yield?

Premium Investing Services